ATE135568T1 - Acetazolamide formulierung mit verzögerter wirkstoffabgabe - Google Patents

Acetazolamide formulierung mit verzögerter wirkstoffabgabe

Info

Publication number
ATE135568T1
ATE135568T1 AT92108329T AT92108329T ATE135568T1 AT E135568 T1 ATE135568 T1 AT E135568T1 AT 92108329 T AT92108329 T AT 92108329T AT 92108329 T AT92108329 T AT 92108329T AT E135568 T1 ATE135568 T1 AT E135568T1
Authority
AT
Austria
Prior art keywords
acetazolamide
release formulation
delayed
release
drug
Prior art date
Application number
AT92108329T
Other languages
English (en)
Inventor
Nicholas Ian Payne
David Parker
Angela Catherine Potts
Laurence Charles Staines
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE135568T1 publication Critical patent/ATE135568T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT92108329T 1991-06-11 1992-05-18 Acetazolamide formulierung mit verzögerter wirkstoffabgabe ATE135568T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9112495A GB2256587A (en) 1991-06-11 1991-06-11 Acetazolamide in sustained release form

Publications (1)

Publication Number Publication Date
ATE135568T1 true ATE135568T1 (de) 1996-04-15

Family

ID=10696429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92108329T ATE135568T1 (de) 1991-06-11 1992-05-18 Acetazolamide formulierung mit verzögerter wirkstoffabgabe

Country Status (11)

Country Link
EP (1) EP0540813B1 (de)
AT (1) ATE135568T1 (de)
CA (1) CA2070877C (de)
DE (1) DE69209228T2 (de)
DK (1) DK0540813T3 (de)
ES (1) ES2086576T3 (de)
FI (1) FI101855B1 (de)
GB (1) GB2256587A (de)
GR (1) GR3019751T3 (de)
NO (1) NO922282L (de)
ZA (1) ZA924242B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
JP2007523664A (ja) 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ 医薬組成物用サシェ
EP1547601A1 (de) 2003-12-23 2005-06-29 Ferring B.V. Beschichtungsverfahren
KR20100049500A (ko) 2007-03-15 2010-05-12 쉐링 코포레이션 글루칸 신타제 억제제로서 유용한 피리다지논 유도체
CN102949377B (zh) * 2012-11-28 2015-05-27 河南中帅医药科技股份有限公司 乙酰唑胺缓释胶囊及其制备方法
CN106822015A (zh) * 2017-03-27 2017-06-13 华益药业科技(安徽)有限公司 乙酰唑胺缓释片及其制备方法
CN113855648B (zh) * 2021-12-03 2022-02-25 北京联嘉医药科技开发有限公司 一种乙酰唑胺缓释胶囊及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3671633A (en) * 1971-05-10 1972-06-20 American Cyanamid Co Process for tabletting acetazolamide
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
GB2135879B (en) * 1983-03-07 1986-05-21 Ciba Geigy Ag Pharmaceutical preparations with uniform elution properties
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
EP0418597A3 (en) * 1989-09-21 1991-11-27 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form

Also Published As

Publication number Publication date
FI922698A (fi) 1992-12-12
ES2086576T3 (es) 1996-07-01
GB2256587A (en) 1992-12-16
GR3019751T3 (en) 1996-07-31
NO922282L (no) 1992-12-14
DE69209228D1 (de) 1996-04-25
EP0540813A1 (de) 1993-05-12
ZA924242B (en) 1993-03-31
GB9112495D0 (en) 1991-07-31
FI101855B (fi) 1998-09-15
DK0540813T3 (da) 1996-07-22
DE69209228T2 (de) 1996-11-21
CA2070877C (en) 2003-02-11
FI101855B1 (fi) 1998-09-15
EP0540813B1 (de) 1996-03-20
FI922698A0 (fi) 1992-06-10
NO922282D0 (no) 1992-06-10
CA2070877A1 (en) 1992-12-12

Similar Documents

Publication Publication Date Title
ATE64091T1 (de) Tablette mit verzoegerter freisetzung.
ATE75936T1 (de) Zusammensetzungen mit verzoegerten wirkstoffabgaben.
DE3855852T2 (de) Kugelförmige Granula mit Kern sowie deren Herstellung
DE68910773T2 (de) Granulate mit Kern und ihre Herstellung.
DE69431247D1 (de) Oxybutyninformulierungen mit gesteuerter freisetzung
CA2046830A1 (en) Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
FI954989A (fi) Lääkelaastari
SE9102072D0 (sv) Oral, fast, farmaceutisk doseringsform med styrd frisaettning
IT8719773A0 (it) Anello d'attrito per frizioni oppure per freni, procedimento e dispositivo per la realizzazione dell'anello d'attrito stesso.
DK288987D0 (da) Et afgivelsessystem til doseringsformerne forhalet afgivelse, samt dettes fremstilling
ATE184196T1 (de) Diltiazem enthaltende arzneimittel mit verzögerter wirkstoffabgabe
FI901956A0 (fi) Nya naftalenylalkyl-3h-1,2,3,5 -oxatiadiazol-2-oxider anvaendbara som antihyperglykemiska medel.
DE68911027T2 (de) Pheromondispenser mit verlängerter Freisetzung.
DE68920697D1 (de) Insektenvertreibungsmittel mit gesteuerter Freisetzung.
ATE135568T1 (de) Acetazolamide formulierung mit verzögerter wirkstoffabgabe
TR26943A (tr) Suda cözünebilir veya suda dagilabilir pestisid granülleri.
DE3881208D1 (de) Schaedlinge abweisende mikrokapseln mit verzoegerter abgabe.
DK15789A (da) Azolsubstituerede cycloalkanolderivater, fremgangsmaade til fremstilling deraf samt anvendelse af derivaterne som landbrugs- og havebrugsfungicider.
FR2661070B1 (fr) Compositions insecticides a base de chrysanthemate de 2,4-dioxo-1-(2-propynyl) imidazolidine-3-ylmethyle.
DE69114623D1 (de) Regelungssystem des Typs mit zwei Freiheitsgraden.
EP0246331A4 (de) Insektizide zusammensetzung.
FI901955A0 (fi) Nya naftalenyl-3h-1,2,3,5-oxatiadiazol -2-oxider anvaendbara som, antihyperglykemiska medel.
IT8822273A0 (it) Procedimento per la preparazione di 1,2-difluoro-1,1,2,2tetacloroetano sostanzialmente privo dell'isomero 1,1-difluoro 1,2,2,2-tetracloroetano.
SV1988000015A (es) Procedimiento para preparar pirazolinas, ref. p-sal-44,240.
IT1295210B1 (it) Concime od integratore per le piante, a base di propoli e procedimento per la fabbricazione e per l'uso di tale concime.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee